Combined Diagnostic Efficacy of Liquid-Based Cytology and Hpv Testing in the Early Detection of Cervical Cancer
Downloads
Background: Cervical cancer (CC) remains one of the leading causes of cancer-related morbidity and mortality among women worldwide. Detection at the precancerous stage substantially improves treatment outcomes and survival. Objective: To evaluate the diagnostic sensitivity and specificity of liquid-based cytology (LBC) combined with high-risk human papillomavirus (hrHPV) testing (co-testing) compared with the conventional Papanicolaou (Pap) smear in detecting cervical precancerous lesions and early-stage cancer. Methods: In this prospective study, 240 women aged 25–60 years were randomized into two equal groups. Group I (n=120) underwent conventional Pap cytology; Group II (n=120) underwent LBC combined with PCR-based hrHPV testing. Final diagnoses were established by colposcopy and histopathological examination of directed biopsies. Results: The sensitivity of co-testing for CIN II+ lesions (moderate-to-severe dysplasia and worse) was 94.2%, versus 68.5% for the conventional Pap test (p<0.001). The false-negative rate was 4.5 times lower in Group II (4.1% vs 18.3%; p<0.001), and no LBC specimen was unsatisfactory, compared with 9.2% of conventional smears. Conclusion: Combining liquid-based cytology with hrHPV testing significantly improves the early diagnostic accuracy of cervical cancer screening and is a promising strategy for screening programs.
[1] H. Sung et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 71, no. 3, pp. 209–249, 2021.
[2] J. M. M. Walboomers et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” J. Pathol., vol. 189, no. 1, pp. 12–19, 1999.
[3] World Health Organization, WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention, 2nd ed. Geneva, Switzerland: WHO, 2021.
[4] J. Cuzick et al., “Overview of the European and North American studies on HPV testing in primary cervical cancer screening,” Int. J. Cancer, vol. 119, no. 5, pp. 1095–1101, 2006.
[5] E. T. H. Fontham et al., “Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society,” CA Cancer J. Clin., vol. 70, no. 5, pp. 321–346, 2020.
[6] R. Nayar and D. C. Wilbur, Eds., The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes, 3rd ed. Cham, Switzerland: Springer, 2015.
[7] G. Ronco et al., “Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials,” Lancet, vol. 383, no. 9916, pp. 524–532, 2014.
[8] H. C. Kitchener et al., “HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): A randomised controlled trial,” Lancet Oncol., vol. 10, no. 7, pp. 672–682, 2009.
[9] T. C. Wright, Jr. et al., “Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test,” Gynecol. Oncol., vol. 136, no. 2, pp. 189–197, 2015.
[10] M. Arbyn, C. Bergeron, P. Klinkhamer, P. Martin-Hirsch, A. G. Siebers, and J. Bulten, “Liquid compared with conventional cervical cytology: A systematic review and meta-analysis,” Obstet. Gynecol., vol. 111, no. 1, pp. 167–177, 2008.
[11] M. P. Oltieva et al., “Epidemiology of high-risk HPV in Uzbekistan among 44,000 women—Genotypes, risk profiles and screening needs in Uzbekistan,” BMC Infect. Dis., vol. 25, Art. no. 1721, 2025, doi: 10.1186/s12879-025-12096-7.
[12] I. P. Sharipova et al., “Optimizing human papillomavirus (HPV) screening: Urine sample analysis and associated factors in Uzbekistan,” Cureus, vol. 16, no. 9, Art. no. e69816, 2024, doi: 10.7759/cureus.69816.
[13] D. Z. Mamarasulova, D. B. Isakova, and G. B. Abdullakhonova, “Testing for human papillomavirus in primary screening of cervical pathology (in Russian),” Doktor Axborotnomasi, no. 1, pp. 158–161, 2022.
[14] G. Koliopoulos et al., “Cytology versus HPV testing for cervical cancer screening in the general population,” Cochrane Database Syst. Rev., no. 8, Art. no. CD008587, 2017, doi: 10.1002/14651858.CD008587.pub2.
[15] G. S. Ogilvie et al., “Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The HPV FOCAL randomized clinical trial,” JAMA, vol. 320, no. 1, pp. 43–52, 2018.
[16] R. B. Perkins et al., “2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors,” J. Low. Genit. Tract Dis., vol. 24, no. 2, pp. 102–131, 2020.
Copyright (c) 2026 American Journal of Biomedicine and Pharmacy

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

